Rituximab in patients with CIDP: A report of 13 cases and review of the literature

Autor: Benedetti, Luana, Briani, Chiara, Franciotta, Diego, Fazio, Raffaella, Paolasso, Ilaria, Comi, Cristoforo, Luigetti, Marco, Sabatelli, Mario, Giannini, Fabio, Mancardi, Giovanni Luigi, Schenone, Angelo, Nobile-Orazio, Eduardo, Cocito, Dario
Přispěvatelé: Department of Neurology, Osp. S. Andrea, La Spezia, Department of Neurosciences, University of Padova, Laboratory of Neuroimmunology, IRCCS, Neurological Institute 'C. Mondino', University of Pavia, Pa, University of Pavia, Department of Neurology, IRCCS San Raffaele, Milano, Neurologia I, Department of Neuroscience, A.S.O. San Giovanni Battista, Torino, Interdisciplinary Research Center of Autoimmune Disease (IRCAD), A. Avogadro, University of Eastern, Department of Neuroscience, Catholic University, Roma, Department of Neuroscience, University of Siena, Siena, Department of Neuroscience, Ophtalmology and Genetics, Genova, Department Neurological Sciences, Milan University, IRCCS Humanitas Clinical Institute, Rozzano, M
Jazyk: angličtina
Rok vydání: 2010
Předmět:
Zdroj: Journal of Neurology, Neurosurgery and Psychiatry
Journal of Neurology, Neurosurgery and Psychiatry, BMJ Publishing Group, 2010, 82 (3), pp.306. ⟨10.1136/jnnp.2009.188912⟩
ISSN: 0022-3050
1468-330X
DOI: 10.1136/jnnp.2009.188912⟩
Popis: International audience; Background: A few case reports have shown controversial results of rituximab efficacy in patients with CIDP. Objective: To analyze the efficacy of rituximab in a large CIDP cohort. Methods: A retrospective, observational and multicenter study on the use of rituximab in CIDP. We treated 13 Italian CIDP patients with rituximab after the partial or complete lack of efficacy of conventional therapies. Eight patients had co-occurring haematological diseases. Patients who improved by at least two points in standard clinical scales, or who reduced or discontinued the pre-rituximab therapies, were considered as responders. Results: Nine patients (7 with haematological diseases) responded to rituximab: six of them, who were non-responders to conventional therapies, improved clinically, and the other three maintained the improvement that they usually achieved with intravenous Ig or plasma exchange. Significantly associated with shorter disease duration, rituximab responses started after a median period of 2.0 months (range, 1-6), and lasted for a median period of 1 year (range, 1-5). Conclusions: Rituximab seems to be a promising therapeutic choice when it targets both CIDP and co-occuring haematological diseases. Timely post-onset administration of rituximab seems to be associated with better responses.
Databáze: OpenAIRE
Externí odkaz: